Vasco Pharmacy (Vitalab Pharmacy, Incorporated), Phoenix, AZ
Is Vasco Pharmacy (Vitalab Pharmacy, Incorporated) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Vasco Pharmacy (Vitalab Pharmacy, Incorporated) hold a Arizona pharmacy license?
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054016668 for VITALAB PHARMACY INC (dba THE COMPOUNDING CENTER PHARMACY), PHOENIX, AZ, status CHANGE OF OWNERSHIP and license 054021209 for VITALAB PHARMACY INC, PHOENIX, AZ, status CHANGE OF OWNERSHIP, as of Nov 13, 2026.
Has Vasco Pharmacy (Vitalab Pharmacy, Incorporated) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jan 10, 2019), 1 warning letter close-out (Feb 6, 2020), 1 state referral letter (Feb 6, 2020) and 1 FMD-145 letter (Feb 6, 2020) for Vasco Pharmacy (Vitalab Pharmacy, Incorporated). State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Reprimand” dated Dec 2, 2017, case 2016011188 on nonresident license 054016668. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Vitalab Pharmacy, Incorporated; Vasco Pharmacy
- Location
- Phoenix, AZ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Feb 6, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 6 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Vitalab Pharmacy, Incorporated (dba Vasco Pharmacy), a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Feb 6, 2020 | Warning letter close-out | Warning Letter Close Out Issued 02/06/2020 | Not linked by FDA |
| Feb 6, 2020 | State referral letter | Referral Letter to the Arizona State Board of Pharmacy dated 02/06/2020 | FDA copy (archived) |
| Feb 6, 2020 | FMD-145 letter | FMD-145 Issued 02/06/2020 | FDA copy (archived) |
| Aug 2, 2019 | Form 483 | 483 Issued 08/02/2019 | FDA copy (archived) |
| Jan 10, 2019 | Warning letter | Warning Letter (01/10/2019) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Vitalab Pharmacy, Inc., Phoenix, AZ (FEI number 3007816026), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 2, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3007816026 | 1099774 |
Form 483s FDA has published for this site
- Aug 2, 2019: Form 483 to Vitalab Pharmacy, Inc., published Oct 17, 2019. fda.gov
- Apr 16, 2018: Form 483 to Vitalab Pharmacy, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 6 numbered observations in all, across 2 inspections ending Apr 4, 2018 to Aug 2, 2019. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 22, 2019 to Aug 2, 2019: 1 observation
- Firm on the cover
- Vitalab Pharmacy, Inc., DBA Vasco Rx Specialty Pharmacy, 4045 East Bell Road, Suite 163, Phoenix, AZ 85032
- FEI number
- 3007816026
- Establishment type on the cover
- producer of sterile and non-sterile drngs THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; ANO DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED. OR Pl.AN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.
- FDA district office on the cover
- Denver District Office 6th Avenue and Kipling Street, Building 20 Denver, CO 80225 303-236-30 17 Industry Information: www.fda.gov/oc/industry
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically, production personnel use <Redacted B4> to produce all non-sterile oral solutions and suspensions which contain <Redacted B4> ! Your firm does not assess microbial or <Redacted B4> of <Redacted B4> Production personnel used <Redacted B4>, lot <Redacted B4> to produce more than 50 finished products including Miracle Mouthwash, lot 07092019@146; and Potassium Bromide, lot 071920 l 9@153.
Inspection Mar 26, 2018 to Apr 4, 2018: 5 observations
- Firm on the cover
- 4045 E. Bell Road, Suite 163 Vitalab Phannacy, Incorporated (dba Vasco Pharmacy), CODE
- FEI number
- 3007816026
- Establishment type on the cover
- · Producer of Sterile and Non-Sterile Drugs Phoenix, AZ 85032
- FDA district office on the cover
- Denver, CO 80225-008.7
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
: You had inadequate HEPA filter coverage and airflow over tbe area which sterile product was exposed.
Specifically, your firm's <Redacte d B4> laminar airflow hood, located in the non-hazardous buffer room, does not provide sterile-filtered air moving at the same speed and in the same direction with no or minimal cross-over of air streams to the aseptic processing surface, as demonstrated by your most recent smoke study evaluation condu cted on 11/14/2017.
Current products aseptically produced in this hood are: TriMix, Methylcobalamin, and Methionine/Inositol/ Choline/Bl2.
Observation 2
: Disinfecting agents and cleaning wipes used in the ISO 5 Classified aseptic processing areas were not sterHe.
Specifically, your firm utilizes non-sterile, 12"x12" clean room wipes, to disinfect the lSO 5 classified aseptic processing area, to disinfect materials introduced into the ISO 5 work space, and as a placemat to rest sterile items placed on the ISO 5 work surface.
Observation 3
: Personnel engaged in aseptic processing were observed with exposed upper face.
Specifically, your firm does not use a full-face plate during aseptic processing that addresses exposed eyes/eye o rbital area. On 3/28/18, I observed your technician's head center the <Redac ted B4> laminar air flow hood by four to six inches, underneath the glass shield, exposing his face to the HEPA filtered air while he was sanitizi
ng rubber stoppers of vials and the neck of ampules wit h S ter ile <Redacted B4> prior to the int rod
uction o f a <Redacted B4>.
Observation 4
: Media fill studies are not conducted to closely simulate aseptic production operations.
Specifically, a media fill or process stimulation has not been performed for all your aseptically prepared formulations. For example, a media fill has not been performed for your h ighest volume, most manually intensive, and most exposed formulation. <R edacted B4>
Observation 5
: Personnel manually contacted the inner surface of the container closure during aseptic production.
Specifically, during aseptic processing on 3/27/18, I observed your technici~n hand stoppering vials with her left hand while filling vials with her right hand. During this process, the technician's hand came into contact with the inner surface of one of the stoppers. The product involved was ~-Progesterone 50mg/mL in Ethyl Oleate Injection.
State board of pharmacy records
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054016668 | LICENSED PHARMACY | VITALAB PHARMACY INC (dba THE COMPOUNDING CENTER PHARMACY) | PHOENIX, AZ | CHANGE OF OWNERSHIP |
| 054021209 | LICENSED PHARMACY | VITALAB PHARMACY INC | PHOENIX, AZ | CHANGE OF OWNERSHIP |
- Dec 2, 2017: “Reprimand”, license 054016668, case 2016011188, VITALAB PHARMACY INC, PHOENIX, AZ. Reason given in the record: “due to a sister-state discipline in the state of Arizona.” Board list
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Illinois Department of Financial and Professional Regulation license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.